Landberg, N
Hansen, N
Askmyr, M
Ågerstam, H
Lassen, C
Rissler, M
Hjorth-Hansen, H
Mustjoki, S
Järås, M
Richter, J
Fioretos, T
Article History
First Online: 12 June 2015
Competing interests
: MJ and TF are cofounders and have equity ownership in Cantargia AB (Ideon Medical Village, Lund, Sweden) formed with Lund University Bioscience AB. JR has stock options in Cantargia AB and has received honoraria from Novartis and Bristol-Myers Squibb. SM has received research funding from Novartis, Bristol-Myers and Squibb and Pfizer and honoraria from Novartis and Bristol-Myers and Squibb. The remaining authors declare no conflict of interest.